Fast Track Designation (FTD) recognizes NOUS-209’s potential to address a serious condition with significant unmet medical need in Lynch Syndrome ...

FDA fast track status was supported by two monotherapy responses in MSI-H colorectal cancer, including one complete response and one partial response, both durable beyond 80 weeks. Suplexa uses ...

Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, ...

Fast track status supports expedited development/review for a serious hematologic malignancy with limited second-line therapy after HMA failure. CyTAC engineering merges small-molecule CCR2 binding ...

MNV-201, a mitochondrial cell therapy, received FDA fast track designation for myelodysplastic syndrome, highlighting its potential to address mitochondrial dysfunction in this serious blood disorder.

Autobahn expects topline data from the ongoing Phase II AMPLIFY-BD trial in adjunctive bipolar depression in the second ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Please provide your email address to receive an email when new articles are posted on . VTx-002 targets proteins that play a significant role in neurodegenerative disease. Enrollment in and ...

ADCE-D01 targets the uPARAP protein in sarcomas, delivering medication directly to cancer cells, showing promise in early studies. The ADCElerate1 trial evaluates ADCE-D01's safety, tolerability, ...

Please provide your email address to receive an email when new articles are posted on . CS1 is an oral histone deacetylase inhibitor that has been shown to be well tolerated in patients with PAH in a ...